Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Tefferi A, Barbui T.
Am J Hematol. 2023 Sep;98(9):1465-1487. doi: 10.1002/ajh.27002. Epub 2023 Jun 26.
PMID:37357958
Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2- and CALR-mutated essential thrombocythemia-A Mayo Clinic study of 200 pregnancies.
Gangat N, Singh A, Ilyas R, Loscocco GG, Elliott M, Begna K, Pardanani A, Tefferi A.
Am J Hematol. 2024 Oct;99(10):1862-1869. doi: 10.1002/ajh.27416. Epub 2024 Jun 12.
Combined thrombophilic risk factors and essential thrombocythemia in patient with recurrent venous thromboembolic episodes-thirty-three-year follow-up.
Antonijevic N, Stanojevic M, Milosevic R, Djordjevic V, Jaukovic M, Vukcevic V, Kovac M, Mikovic D, Radojkovic D, Vasiljevic Z.
Association of Treatments for Myeloproliferative Neoplasms During Pregnancy With Birth Rates and Maternal Outcomes: A Systematic Review and Meta-analysis.
Maze D, Kazi S, Gupta V, Malinowski AK, Fazelzad R, Shah PS, Shehata N.
JAMA Netw Open. 2019 Oct 2;2(10):e1912666. doi: 10.1001/jamanetworkopen.2019.12666.
PMID:31584685
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.
Bose P, Xiao Z, Hasselbalch HC, Prchal JT, Duan M, Yacoub A, Rampal R, Kiladjian JJ, Hobbs GS, Tashi T, Shimoda K, Kirito K, Gill H, Hou HA, Lee SE, Huang J, Li B, Qin A, Yu LH, Mascarenhas JO, Mesa RA.